Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of MK-5172 + MK-3682 with MK-8742 or MK-8408 in chronic hepatitis C virus infection
2014-003347-35Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of grazoprevir, uprifosbuvir, verubecestat, ruzasvir and ribavirin in chronic hepatitis C (CHC) (3 arms), sponsored by Merck & Co. Primary endpoint: SVR12. Started Sep 2014; status: completed.
02
Drugs
grazopreviruprifosbuvirverubecestatruzasvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-003347-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003347-35.